
Orelabrutinib Wins Approval in China for First-Line CLL and SLL
China’s National Medical Products Administration (NMPA) has approved the BTK inhibitor orelabrutinib (ICP-022) for the first-line treatment of patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).1 Orelabrutinib was …